439 related articles for article (PubMed ID: 18096812)
1. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
2. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
Dragic T; Trkola A; Thompson DA; Cormier EG; Kajumo FA; Maxwell E; Lin SW; Ying W; Smith SO; Sakmar TP; Moore JP
Proc Natl Acad Sci U S A; 2000 May; 97(10):5639-44. PubMed ID: 10779565
[TBL] [Abstract][Full Text] [Related]
3. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
4. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
5. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.
Nishikawa M; Takashima K; Nishi T; Furuta RA; Kanzaki N; Yamamoto Y; Fujisawa J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4708-15. PubMed ID: 16251315
[TBL] [Abstract][Full Text] [Related]
6. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
7. Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor.
Saita Y; Kondo M; Shimizu Y
Int Immunopharmacol; 2007 Dec; 7(12):1528-34. PubMed ID: 17920529
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.
Labrecque J; Metz M; Lau G; Darkes MC; Wong RS; Bogucki D; Carpenter B; Chen G; Li T; Nan S; Schols D; Bridger GJ; Fricker SP; Skerlj RT
Virology; 2011 May; 413(2):231-43. PubMed ID: 21388649
[TBL] [Abstract][Full Text] [Related]
9. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket.
Castonguay LA; Weng Y; Adolfsen W; Di Salvo J; Kilburn R; Caldwell CG; Daugherty BL; Finke PE; Hale JJ; Lynch CL; Mills SG; MacCoss M; Springer MS; DeMartino JA
Biochemistry; 2003 Feb; 42(6):1544-50. PubMed ID: 12578367
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
[TBL] [Abstract][Full Text] [Related]
11. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach.
Gadhe CG; Kothandan G; Cho SJ
J Biomol Struct Dyn; 2013; 31(11):1251-76. PubMed ID: 23153179
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication.
Takashima K; Miyake H; Furuta RA; Fujisawa JI; Iizawa Y; Kanzaki N; Shiraishi M; Okonogi K; Baba M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3538-43. PubMed ID: 11709336
[TBL] [Abstract][Full Text] [Related]
13. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
[TBL] [Abstract][Full Text] [Related]
14. Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.
Asin-Milan O; Sylla M; El-Far M; Belanger-Jasmin G; Haidara A; Blackburn J; Chamberland A; Tremblay CL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7565-9. PubMed ID: 25267674
[TBL] [Abstract][Full Text] [Related]
15. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
16. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
17. Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
Seibert C; Ying W; Gavrilov S; Tsamis F; Kuhmann SE; Palani A; Tagat JR; Clader JW; McCombie SW; Baroudy BM; Smith SO; Dragic T; Moore JP; Sakmar TP
Virology; 2006 May; 349(1):41-54. PubMed ID: 16494916
[TBL] [Abstract][Full Text] [Related]
18. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
[TBL] [Abstract][Full Text] [Related]
19. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
[TBL] [Abstract][Full Text] [Related]
20. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
